peptidecalc
home / articles / Semaglutide Half-Life: How Long It Stays in the Body
article

Semaglutide Half-Life: How Long It Stays in the Body

A measurement-only look at semaglutide pharmacokinetics: a one-week half-life, why the molecule lasts, and what the decay curve looks like.

2026-11-14 · 8 min read

Semaglutide Half-Life: How Long It Stays in the Body
Photo: Mikhail Nilov / Pexels

Semaglutide has one of the longest elimination half-lives of any peptide in routine clinical use. The FDA prescribing information for the once-weekly injectable product states that the half-life of semaglutide is approximately 1 week, so material from a single administration is still measurable in plasma more than a month later. That one number explains most of what people observe about the compound: a slow build-up in the blood, a long run-up to a stable level, and a long tail after the final injection. This article covers the measurement side only, meaning the published pharmacokinetics and the arithmetic of exponential decay.

Half-life is the time it takes for a quantity to fall to half its value. It is a property of a decay process, not a stopwatch on the whole molecule, so it does not mean the substance is gone after one half-life. It means half of what was there is left. Because the decay is exponential, each successive half-life removes half of what remains rather than a fixed amount. If that distinction is new, our explainer on how to read a peptide half-life works through it slowly before you try to interpret any specific compound.

What the prescribing information reports

The clinical pharmacology section of the FDA label for the once-weekly injection is the primary source for the figures below. The oral tablet formulation of semaglutide has its own separate label, with a different absorption profile but a similar elimination half-life, because the molecule being eliminated is the same.

ParameterReported value (once-weekly injection)
Elimination half-lifeApproximately 1 week
Time to maximum plasma concentration1 to 3 days after injection
Plasma protein bindingGreater than 99%, mainly to albumin
Mean apparent volume of distributionApproximately 12.5 L
Mean apparent clearanceApproximately 0.05 L/h
Time to steady state4 to 5 weeks of once-weekly administration
Excretion routesUrine and faeces, with roughly 3% appearing in urine as intact semaglutide

Two of those lines deserve attention together. An apparent volume of distribution of about 12.5 L is small, close to extracellular fluid volume, which tells you the molecule stays largely in the circulation rather than spreading widely into tissue. An apparent clearance of about 0.05 L/h is very slow. A small distribution volume combined with slow clearance is exactly the combination that produces a long half-life, since half-life scales with volume divided by clearance.

For the oral formulation, the label reports a much earlier time to maximum concentration (around 1 hour after intake, because absorption happens in the stomach with an absorption enhancer) alongside a half-life that is still described as approximately 1 week. Absorbed amount and absorption speed differ between the two products. Elimination does not.

Why semaglutide lasts so long

Native glucagon-like peptide-1, the hormone semaglutide is modelled on, survives only about 1.5 to 2 minutes in plasma according to the GLP-1 physiology literature. Getting from two minutes to one week is a deliberate piece of molecular engineering, described by Lau and colleagues in the Journal of Medicinal Chemistry (2015) in their account of how semaglutide was selected. Three structural changes do the work.

  • Resistance to DPP-4. Dipeptidyl peptidase-4 is the enzyme that clips native GLP-1 near its N-terminus within minutes. Semaglutide substitutes an unnatural amino acid, alpha-aminoisobutyric acid, at position 8, the residue DPP-4 needs to make that cut. The enzyme can no longer act efficiently, so the fastest degradation route is largely closed.
  • Albumin binding through a fatty acid side chain. A C18 fatty diacid is attached to the lysine at position 26 through a hydrophilic spacer. That chain binds reversibly to serum albumin, the most abundant protein in plasma. The label reports greater than 99% protein binding. A peptide travelling attached to albumin behaves like a large protein, which keeps it from being filtered out by the kidneys and creates a slowly releasing circulating reservoir.
  • Slow metabolic breakdown. An absorption, metabolism and excretion study by Jensen and colleagues, published in the European Journal of Pharmaceutical Sciences (2017), found that semaglutide is cleared by proteolytic cleavage of the peptide backbone together with sequential beta-oxidation of the fatty acid side chain. Both are slow, general-purpose processes rather than a single fast enzymatic step.

The same strategy, with different side chains and spacers, is what separates long-acting analogues from short-acting ones generally. Our reference table of peptide half-lives puts semaglutide next to research peptides that clear in minutes, which makes the scale of the difference easier to see. The tirzepatide half-life article covers a closely related case with a comparable weekly profile.

How many half-lives until it is essentially cleared

The convention in pharmacokinetics is that a substance is essentially eliminated after about 5 half-lives, at which point roughly 3% of the original amount remains. With a half-life of approximately 1 week, that puts semaglutide at about 5 weeks. The table below is pure arithmetic applied to the label figure, not a measurement of any individual.

Half-lives elapsedApproximate timeFraction remaining
0Time of the last injection100%
1About 1 week50%
2About 2 weeks25%
3About 3 weeks12.5%
4About 4 weeks6.25%
5About 5 weeksAbout 3%
6About 6 weeksAbout 1.6%

Notice that the curve never actually reaches zero. It approaches it. The 5 half-life convention is a practical cut-off chosen because what remains is usually below the level that produces a measurable effect, not a point where the molecule disappears. The FDA label reflects the same logic when it notes that semaglutide will still be present in the circulation for roughly 5 weeks after the last administration.

Steady state, and why it takes about a month

When a substance is given repeatedly at an interval close to its own half-life, the amount in the body accumulates until input and elimination balance. That balance point is steady state. The label reports steady state after 4 to 5 weeks of once-weekly administration, which is the same 4 to 5 half-lives as the clearance calculation, running in the opposite direction.

The mathematics is symmetrical. Elimination removes half of what is present each week. A weekly input adds a fixed amount each week. In week one, roughly half of the first input is still around when the second arrives. In week two, half of that leftover plus half of the second input survives into week three, and so on. The leftover grows quickly at first, then less and less, converging on a plateau at about double the level seen after a single administration. That accumulation ratio of roughly two is characteristic of any schedule where the interval matches the half-life.

Two practical consequences follow from the arithmetic. First, plasma levels keep rising for about a month after any change in input, which is why nothing about this compound settles fast. Second, the trough between weekly administrations is shallow: losing half of a plateau level that is twice the single-administration peak leaves a relatively flat curve, which is the point of designing a weekly molecule in the first place.

What the curve looks like on the decay calculator

Enter a half-life of 168 hours (7 days) into our peptide half-life decay calculator and you can watch the full shape rather than reading percentages off a table. Starting from an arbitrary 100 units, the model drops to 50 after a week, 25 after two, and flattens into a long shallow tail from about week four onward. The steepest part of the curve is the first week, and the last half of the total elapsed time removes only a few percent of the starting amount.

Working in hours rather than days is usually clearer for comparisons, since most research peptides have half-lives measured in minutes or hours. Some regulatory assessment documents give a figure close to 165 hours for semaglutide, which rounds to the same week; entering 165 or 168 changes the curve so little that it is invisible on the chart. If you want a walkthrough of the chart axes themselves, our guide on how to read a decay curve covers log versus linear scales and where the common misreadings happen.

One point on scope: the calculator models a single exponential decay from one stated half-life. It does not model absorption, which for semaglutide takes 1 to 3 days to reach peak concentration, and it does not model repeated inputs. So the curve describes the elimination phase after the last administration, which is the question most people are actually asking.

Why a single number is still an approximation

Approximately 1 week is a population average. Published pharmacokinetic analyses report exposure varying with body weight, which is expected for a molecule confined to a small distribution volume. The label notes that renal impairment, hepatic impairment, age, sex and race did not produce changes in semaglutide pharmacokinetics considered clinically relevant, which is itself a consequence of the clearance mechanism: breakdown by widespread proteolysis and beta-oxidation does not depend on one organ or one enzyme the way many small molecules do.

Assay differences matter too. A half-life derived from measuring intact semaglutide is not the same as one derived from measuring total radiolabelled material, since metabolites persist on their own timeline. When you compare half-life figures across sources, check which quantity was measured before concluding that the numbers disagree. Our overview of what affects peptide half-life lists the structural and analytical variables that move these values around.

Finally, half-life and duration of effect are different measurements. Plasma concentration follows the decay curve; a biological response can outlast or undercut it depending on receptor kinetics. Pharmacokinetics tells you where the molecule is, not what it is doing. If you need the separate arithmetic of converting milligrams into syringe units for a vial you already have, that is handled by the semaglutide units calculator instead.

This article is education only and covers measurement and pharmacokinetics. It is not medical advice, not a recommendation to use any compound, and contains no usage guidance. Pharmacokinetic figures are drawn from the FDA prescribing information and the named published studies above; consult the current label and a qualified healthcare professional for anything clinical.

For research & education only. These tools convert values you enter. They are not medical advice and do not recommend doses. Peptides referenced are for laboratory research use. Consult a licensed professional for any health decision.

Frequently Asked Questions

What is the half-life of semaglutide?
The FDA prescribing information for the once-weekly semaglutide injection states that its elimination half-life is approximately 1 week, which is about 165 to 168 hours. The oral tablet formulation has its own label, and although it is absorbed much faster (peak concentration around 1 hour after intake), its reported half-life is also approximately 1 week. That is because absorption and elimination are separate processes, and the molecule being eliminated is identical.
How long does semaglutide stay in the body after the last injection?
Using the standard convention of about 5 half-lives for essentially complete elimination, roughly 5 weeks. After 1 week about 50% remains, after 2 weeks about 25%, after 3 weeks about 12.5%, and after 5 weeks about 3%. The FDA label itself notes that semaglutide will still be present in the circulation for about 5 weeks after the final administration. Exponential decay never reaches exactly zero, so 5 half-lives is a practical cut-off rather than a disappearance point.
Why is semaglutide's half-life so much longer than natural GLP-1?
Native GLP-1 survives only about 1.5 to 2 minutes because the enzyme DPP-4 cleaves it almost immediately. Semaglutide replaces the amino acid DPP-4 targets with alpha-aminoisobutyric acid, closing that route, and adds a C18 fatty diacid side chain that binds reversibly to albumin in plasma. With over 99% protein binding, the molecule avoids rapid kidney filtration and acts as a slow-release circulating reservoir. Lau and colleagues described this design in the Journal of Medicinal Chemistry in 2015.
How long does semaglutide take to reach steady state?
The label reports steady state after 4 to 5 weeks of once-weekly administration, which is the same 4 to 5 half-lives as the elimination calculation running in reverse. When the interval between administrations matches the half-life, the amount in the body accumulates to roughly double the level reached after a single administration before input and elimination balance. Plasma levels therefore keep rising for about a month after any change in the pattern of input.

Track your protocols in the Peptide Lab app

Save calculations, log injections and get reconstitution reminders — free to start.

Open Peptide Lab

Related tools